Azithromycin + Pyrimethamine + Leucovorin calcium

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Toxoplasmosis, Cerebral

Conditions

Toxoplasmosis, Cerebral, HIV Infections

Trial Timeline

— → —

NCT ID

NCT00000966

About Azithromycin + Pyrimethamine + Leucovorin calcium

Azithromycin + Pyrimethamine + Leucovorin calcium is a phase 1 stage product being developed by Pfizer for Toxoplasmosis, Cerebral. The current trial status is completed. This product is registered under clinical trial identifier NCT00000966. Target conditions include Toxoplasmosis, Cerebral, HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00000966	Phase 1	Completed	—	—	Toxoplasmosis, Cerebral

Other Products from Pfizer